I find it hard to believe that they would be able to do this without getting stung by regulators. Naked short selling isn't easy, call your broker and ask them if you can do it. What you will find that is unless youre a very high net worth client, and have the background in trading - ie not the usual person that's dabbling in trading, they will laugh you off the phone. Why bother focusing on the negative anyways. APH has a lot going for it, although I will acknowledge that they did mis-step with their moves in the US. I'm one for looking at companies on the way up (expanding business, addressing a market need, supportive management, etc) and came across this one.
It just listed this month. I'll paste what someone else posted on the bullboard so I can't speak for their analysis but it's a good summary of why you might want to consider holding some shares in the company. Oh and insiders continue to buy shares on the open market, even after the listed transactions from below. If you can't beat the market players might as well join a good team on the upswing in my opinion. Good luck.
I'm part of an investment club and have decided to put MTEC up for consideration among my closest investment partners. Each month we share our picks. I thought I'd share this here as well. It's strictly my opinion so do your own due diligence.
Investment Thesis on Cannvas Medtech MTEC:CSE Cannvas Medtech is a tech-based business technology provider that focuses on the emerging needs of the Cannabis space. With legalization around the corner, Cannvas Medtech is positioned to provide data to service the needs of multiple market participants – consumers, producers, processors, as well as advisors, analysts, and government participants.
Market Action Since listing on the CSE, July 3
rd, the shares have a low of $0.25 and a high of $1. The high occurred on July 5
th on extreme buying with high volume and subsequently pulled back to the current base in mid $0.30’s.
Insider Transactions Insiders have been purchasing shares both on the open market and through the exercise of options (announced July 3
rd).
Most recent transactions include…
CEO Shawn Moniz – July 20
th for 18,000 shares at $0.365
- July 9
th for 3,000 shares at $0.51
- July 3
rd Options Exercised for 750,000 shares at $0.25
COO Steve Loutskou – July 6
th for 71,500 shares at $0.65 to $0.74
- July 3
rd Options Exercised for 800,000 shares at $0.25
News Releases Since listing on the CSE July 3
rd, the company has made 16 releases to investors.
Most recent release headlines include….
July 19
th – Cannvas Partners with Business of Cannabis
July 18
th – Cannvas Lists on the Frankfurt Stock Exchange
July 17
th – Cannvas Planning German Expansion
July 17
th – Cannvas Names Data Protection Officer
July 16
th – Cannvas Signs Strategic Data and Analytics LOI within Hemp Sector
For further details on news releases, please see
https://www.cannvasmedtech.com/.
Opinion
MTEC appears to be one of those intriguing stories that comes on to the market from time to time. There’s clearly a need for data services in the Cannabis sector, and with so many potential markets for this data, it appears that Cannvas Medtech has first mover status in this area. MTEC is also a truly independent data provider with no announced stakes or affiliations for their data collection and as such, this opens the potential market to include all licensed producers. This positions them as the “google” for data in the Cannabis space. Data is aggregated from multiple sources, analyzed, and packaged for sale to those that require it.
It’s also clear that management has aligned itself with shareholders through purchases of shares on the market and through the exercise of options. It is my opinion, that we add this stock to our long term speculative holdings, with an initial target of $2/share. Please have a look and let me know what you think!
Sincerely,
Avner